$1,318.00
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Risk factors
8 Diagnosis
8 Patient segmentation
10 TREATMENT
10 Rate control strategy
10 Rhythm control strategy
11 Medications to prevent thromboembolism
12 Medical procedures or surgery
14 EPIDEMIOLOGY
18 MARKETED DRUGS
18 Atrial fibrillation/flutter
21 SPAF
23 PIPELINE DRUGS
23 Atrial fibrillation/flutter
27 SPAF
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Cardiovascular Catch-Up: AliveCor Launches Card-Size ECG
32 J&J Brings RF Balloon Ablation To Europe
32 FDA Approves Abbott’s Amplatzer Amulet LAA Occluder To Compete With Boston Scientific’s Watchman
33 FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib
34 PROBABILITY OF SUCCESS
34 Atrial fibrillation/flutter
34 SPAF
36 LICENSING AND ASSET ACQUISITION DEALS
36 Boston Scientific Builds Momentum In Electrophysiology
36 Boston Scientific Shoots For Cardiac Ablation Leadership With $387M Farapulse Acquisition
37 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
45 BIBLIOGRAPHY
47 APPENDIX
LIST OF FIGURES
17 Figure 1: Trends in prevalent cases of atrial fibrillation, 2018–27
23 Figure 2: Overview of pipeline drugs for atrial fibrillation/flutter in the US
24 Figure 3: Pipeline drugs for atrial fibrillation/flutter, by company
24 Figure 4: Pipeline drugs for atrial fibrillation/flutter, by drug type
24 Figure 5: Pipeline drugs for atrial fibrillation/flutter, by classification
27 Figure 6: Overview of pipeline drugs for SPAF in the US
27 Figure 7: Pipeline drugs for SPAF, by company
28 Figure 8: Pipeline drugs for SPAF, by drug type
28 Figure 9: Pipeline drugs for SPAF, by classification
31 Figure 10: Key upcoming events in atrial fibrillation
34 Figure 11: Probability of success in the atrial fibrillation/flutter pipeline
35 Figure 12: Probability of success in the SPAF pipeline
39 Figure 13: Clinical trials in atrial fibrillation
39 Figure 14: Top 10 drugs for clinical trials in atrial fibrillation
40 Figure 15: Top 10 companies for clinical trials in atrial fibrillation
40 Figure 16: Trial locations in atrial fibrillation
41 Figure 17: Atrial fibrillation trials status
42 Figure 18: Atrial fibrillation trials sponsors, by phase
LIST OF TABLES
15 Table 1: Prevalent cases of atrial fibrillation, 2018–27
19 Table 2: Marketed drugs for atrial fibrillation/flutter
22 Table 3: Marketed drugs for SPAF
26 Table 4: Pipeline drugs for atrial fibrillation/flutter in the US
29 Table 5: Pipeline drugs for SPAF in the US
37 Table 6: Historical global sales, by drug ($m), 2017–21
38 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!